Whitepapers

Explore our comprehensive whitepapers showcasing how our cutting-edge technology accelerates end-to-end drug discovery. Discover how partnering with us can reduce time, cost and driving innovations from Target Identification to Lead Optimization.

SUBSCRIBE ON SUBSTACK

Latest Whitepapers

4 of 4 Whitepapers

MedGraph^TM - Topaaz

Design novel drug molecules for a target protein using our AI-driven de novo design approach. We combines AI-accelerated screening and physics-based modeling to identify high-potential candidates efficiently.

MedGraph^TM - Rubie

Screen a curated library of compounds, including FDA-approved drugs, investigational drugs, and PubChem/ChEMBL compounds, against a target protein of interest to identify potential binders.

MedGraph^TM - Oopal - FEP

Predict the impact of molecular modifications on binding affinity with FEP, computing binding free energy differences to inform lead optimization and selection.

MedGraph^TM - Topaaz - Medkush

Optimize hit molecules into leads with our MedKush platform, using targeted transformations to enhance properties and fast-track discovery.

Why Medvolt

Accelerate Discovery

Medvolt's AI-powered platform cuts pre-clinical discovery time by 3x, reduces costs by 15x and lowers failure risk by 25%. Enhance your R&D efficiency with our in silico tools.

High-Throughput Data

Enrich your research with Medvolt's proprietary, gold-standard, high-throughput proprietary datasets. Our AI and NLP solutions deliver speed, precision and scalability.

Expert Collaboration

Our experienced, tech-driven team collaborates globally with leading pharma and biotech companies, ensuring impactful, scalable solutions.